Perinatal Infections — TORCH

• Placental invasion and transplacental migration: All TORCH organisms possess tropism for trophoblastic tissue and placental endothelium. Maternal viremia or parasitemia establishes infection in the intervillous space and decidua, followed by penetration of the placental barrier. Viral or parasitic organisms directly traverse trophoblastic cells or exploit Hofbauer cells (placental macrophages) as "Trojan horses" for dissemination. CMV in particular establishes persistent infection within placental macrophages and fibroblasts, maintaining a reservoir for chronic shedding. The integrity of the placental barrier—compromised in early pregnancy when the syncytiotrophoblast is incompletely formed—explains the highest transmission risk in the first trimester, particularly for rubella (85% transmission at <11 weeks) and toxoplasmosis (15% at <13 weeks vs. >90% at >30 weeks, though with less severe manifestations).

• Direct cellular injury via viral replication and immune mechanisms: Once organisms reach fetal tissues, direct cytopathic effects predominate. Rubella virus produces chronic persistent infection characterized by continuous viral replication within infected cells without causing cell lysis—instead triggering prolonged interferon-alpha production and chronic inflammation that impairs cellular differentiation during organogenesis. This explains the critical timing: exposure during lens development (weeks 6–8) causes cataracts, exposure during inner ear development (weeks 7–13) causes sensorineural hearing loss, and cardiac development disruption (weeks 5–9) produces patent ductus arteriosus. CMV similarly establishes chronic infection through manipulation of apoptotic pathways (viral proteins sequester pro-apoptotic factors, allowing infected cell survival while viral replication continues). Extensive viral replication damages developing neural tissue, resulting in lissencephaly, polymicrogyria, and ventriculomegaly. HSV and varicella-zoster virus (VZV) produce acute cytolytic infection with hemorrhagic necrosis of affected tissues; VZV in particular causes selective dorsal root ganglion neurodegeneration explaining the dermatomal distribution of scarring and associated limb hypoplasia. Toxoplasma gondii causes necrotizing inflammation in the brain, eye, and other tissues through direct parasitic invasion and intense Th1-mediated immune response; the parasite preferentially infects microglia and astrocytes, producing diffuse encephalitis with microabscess formation.

• Organogenesis disruption and developmental abnormalities: Beyond direct cytopathic effects, TORCH infections interfere with critical developmental signaling pathways. Rubella induces production of tumor necrosis factor-alpha (TNF-α) and other inflammatory cytokines that suppress differentiation of lens epithelial cells and disrupt the precise developmental timing required for normal cardiac septation and inner ear patterning. CMV triggers exaggerated interferon-gamma production in fetal tissues, creating a pro-inflammatory state that impairs neuronal migration and cortical organization. The result is periventricular calcifications (reflecting areas of ventriculitis and necrosis) and neuronal migration disorders on neuroimaging. Toxoplasmosis causes similar necrotizing encephalitis with subsequent hydrocephalus and intracranial calcifications distributed diffusely throughout white matter and basal ganglia (in contrast to the periventricular predominance of CMV). Congenital syphilis causes spirochete invasion of bone, skin, and neural tissue; the inflammatory response produces osteochondritis and mimics autoimmune disease through immune complex deposition in multiple organs.

• Chronic infection and perinatal transmission routes: Many TORCH organisms establish persistent intrauterine infection that continues after birth. Congenital CMV represents the most common intrauterine infection (0.5–1.0% of births) with ≥10% of infected infants shedding virus in urine and saliva for years, creating nosocomial transmission risk. Congenital rubella can produce lifelong viral shedding from respiratory secretions and urine, with infected infants remaining contagious for months. Perinatal HSV transmission occurs primarily during vaginal delivery through contact with infected birth canal secretions; approximately 30–50% of infants born to mothers with primary genital HSV who deliver vaginally become infected, compared to <5% with recurrent disease (due to maternal IgG antibodies providing partial passive immunity). Varicella acquired in the third trimester carries 10–20% risk of congenital infection; if maternal varicella occurs 5 days before to 2 days after delivery, neonatal varicella develops in up to 50% of infants due to insufficient time for maternal antibody transfer.

• Toxoplasma gondii: Obligate intracellular parasite transmitted to humans via ingestion of oocysts from cat feces or consumption of undercooked meat containing tissue cysts. Maternal seropositivity varies by geography (>80% in France and Central Europe, 10–25% in North America) and socioeconomic status. Immunocompromised pregnant patients (particularly those with HIV/AIDS and CD4 <100 cells/μL) face markedly elevated risk of primary infection and reactivation disease. Congenital transmission occurs almost exclusively with primary maternal infection (up to 60% transmission rate); the risk increases with advancing gestational age (10–15% at <12 weeks, approaching 90% at >36 weeks), though fetal disease severity is inversely related to gestational age at infection.

• Rubella virus: Enveloped togavirus spread via respiratory droplets. Primary maternal infection confers lifelong immunity; congenital transmission occurs only with primary infection during pregnancy. Transmission risk is highest in the first trimester (85% at <11 weeks), declining to 33% at 13–14 weeks and <10% after 20 weeks. Incidence has declined dramatically in countries with universal MMR vaccination but remains significant in unvaccinated populations, recent immigrants, and healthcare workers with unknown immunity. The congenital rubella syndrome (CRS) triad includes cardiac abnormalities (patent ductus arteriosus, peripheral pulmonary artery stenosis), ocular manifestations (cataracts, retinopathy, glaucoma), and sensorineural hearing loss; the "expanded" phenotype includes fetal growth restriction, thrombocytopenia, hepatosplenomegaly, and developmental delay.

• Cytomegalovirus (CMV): Double-stranded DNA herpesvirus with highest epidemiologic prevalence among TORCH agents. Maternal transmission to fetus occurs via hematogenous dissemination during maternal viremia; primary infection carries ~40% fetal transmission risk, while recurrent/reactivation disease carries 0.5–2% risk (lower due to maternal IgG). Up to 10–20% of infants with congenital CMV develop symptomatic disease at birth; the remaining 80–90% are asymptomatic at birth but face 5–15% risk of sequelae including sensorineural hearing loss (most common sequela, occurring in up to 60% of symptomatic cases and 15% of asymptomatic cases), developmental delay, visual impairment, and microcephaly. Maternal CMV seropositivity ranges from 40–80% depending on socioeconomic status, making reinfection or reactivation common in seropositive women.

• Herpes simplex virus (HSV-1 and HSV-2): Neurotropic enveloped DNA virus. Perinatal (neonatal) HSV infection is the most common viral cause of neonatal encephalitis, occurring in approximately 1 in 3,000–5,000 live births. Transmission occurs primarily during vaginal delivery through contact with infected birth canal secretions; primary maternal infection at term carries 30–50% transmission risk, while recurrent infection carries <5% risk. The type of maternal infection determines neonatal disease severity: primary maternal HSV-2 infection at delivery poses highest risk for disseminated neonatal disease (affecting liver, lungs, central nervous system). Intrauterine HSV infection is rare but devastating, associated with microcephaly, chorioretinitis, and cutaneous scarring in a dermatomal distribution.

• Varicella-zoster virus (VZV): Member of herpesvirus family with distinct perinatal manifestations depending on timing. Congenital varicella syndrome (CVS) occurs in 0.4–2.0% of infants born to mothers with primary varicella during the first 20 weeks of gestation, characterized by dermatomal scarring, limb hypoplasia, eye abnormalities (chorioretinitis, cataracts, optic nerve hypoplasia), and microcephaly. Maternal varicella infection 5 days before to 2 days after delivery poses high risk (10–50%) for neonatal varicella, which can progress to disseminated disease with encephalitis and hepatitis if untreated. In contrast, maternal infection before 5 days prior to delivery typically allows sufficient time for maternal antibody transfer, resulting in mild neonatal disease or asymptomatic infection.

• Treponema pallidum (syphilis): Spirochete causing congenital syphilis through hematogenous transplacental transmission; virtually all untreated maternal syphilis results in fetal infection if pregnancy continues beyond the first trimester. Congenital syphilis risk is highest with primary and secondary maternal syphilis (75–95% transmission) and declines with latent disease. Clinical manifestations occur in approximately 40% of infected infants (early congenital syphilis), with neonatal findings including hepatosplenomegaly, rash, jaundice, osteochondritis, and sepsis-like presentation; additional sequelae include stigmata of late congenital syphilis (frontal bossing, saddle nose deformity, Hutchinson teeth, corneal scarring, sensorineural hearing loss) if infection is inadequately treated.

• Parvovirus B19: Small DNA virus causing erythema infectiosum ("fifth disease") in children; pregnant women exposed to infected children face 30–50% transmission risk. Vertical transmission to fetus occurs in 10–60% of primary maternal infections, with critical risk window during second trimester (weeks 9–20) when fetal hematopoiesis is most active. Maternal IgM seropositivity confirms recent infection. Fetal complications include hydrops fetalis (fetal heart failure from severe anemia), intrauterine fetal demise (particularly 9–16 weeks gestation), and rarely, congenital anemia. Unlike other TORCH organisms, parvovirus rarely causes structural birth defects.

• Other causative agents: Enterovirus (particularly coxsackievirus and echovirus) transmission occurs perinatally with risk of neonatal myocarditis, meningitis, and hepatitis. Listeria monocytogenes causes maternal chorioamnionitis and ascending infection, resulting in neonatal bacteremia and meningitis. Group B Streptococcus (GBS) is acquired during passage through infected birth canal. Mycoplasma hominis and Ureaplasma cause chorioamnionitis and neonatal lung disease. Measles and mumps (in unvaccinated populations) cause congenital infection with growth restriction and fetal demise.

• Congenital rubella: Intrauterine growth restriction (IUGR), microcephaly, and cardiac abnormalities on fetal ultrasound. Cardiac findings include patent ductus arteriosus (most common cardiac lesion), peripheral pulmonary artery stenosis, and septal defects. The expanded rubella phenotype includes fetal hepatomegaly, ascites, polyhydramnios, and placental thickening. Amniotic fluid cultures positive for rubella or detection of rubella IgM in fetal blood confirms diagnosis.

• Congenital CMV: Microcephaly (most common finding), periventricular calcifications (pathognomonic for CMV in the fetus), ventriculomegaly, lissencephaly, and IUGR. Periventricular calcifications represent areas of prior ventriculitis and necrosis. Fetal thrombocytopenia and abnormal liver function tests may be detected. Amniotic fluid culture, CMV PCR, or isolation of CMV in fetal urine confirms diagnosis. Fetal MRI demonstrates associated neuronal migration disorders not visible on ultrasound.

• Congenital toxoplasmosis: Intracranial calcifications distributed diffusely in white matter and basal ganglia (distinct from periventricular distribution of CMV), hydrocephalus from aqueductal obstruction, chorioretinitis (particularly affecting the macula), and IUGR. Amniotic fluid PCR for Toxoplasma after 18 weeks gestation provides diagnosis; fetal blood PCR is less sensitive.

• Congenital syphilis: IUGR, hepatomegaly, and in some cases, hydrops fetalis or fetal demise. Nonimmune hydrops develops in severe early infection. Fetal imaging may show placental abnormalities and hepatic changes.

• Congenital varicella syndrome: Dermatomal scarring in a single or few dermatomes (pathognomonic finding), limb hypoplasia (particularly affecting digits), eye abnormalities (chorioretinitis, cataracts, optic nerve hypoplasia), microcephaly, and IUGR. The abnormalities are clustered in time and space, reflecting the timing of varicella infection during organogenesis.

• Parvovirus B19: Hydrops fetalis with fetal ascites, pericardial effusion, and pleural effusion secondary to severe fetal anemia and heart failure; polyhydramnios may also be present. Fetal anemia may be severe (hemoglobin <3 g/dL in extreme cases).

• Congenital rubella syndrome (CRS): Classic triad of cardiac abnormalities, ocular disease, and hearing loss. The "expanded" phenotype includes **microcephaly, developmental delay, fetal growth restriction, hepatosplenomegaly

Maternal (prenatal) evaluation

• Serology first: paired IgM/IgG is the entry test for Toxoplasma, rubella, CMV, VZV, and parvovirus B19. IgM alone is unreliable — it persists for months and cross-reacts — so IgG avidity testing is the confirmatory step: low avidity implies primary infection within roughly the prior few months, high avidity effectively excludes recent primary infection. ACOG advises confirming positive toxoplasma results at a reference toxoplasma serology laboratory before acting on them.
• Universal prenatal screening (ACOG, USPSTF): rubella IgG immunity, syphilis, HIV, and hepatitis B at the first visit; USPSTF and CDC support repeat syphilis testing in the third trimester and at delivery for at-risk populations. Routine CMV and toxoplasma screening is not recommended in the U.S.
• Syphilis algorithm: nontreponemal test (RPR/VDRL) confirmed by treponemal test (TP-PA, FTA-ABS), or the reverse-sequence algorithm; darkfield microscopy of a chancre or placenta is definitive.
• Amniocentesis with PCR is the fetal gold standard: CMV DNA PCR after ~21 weeks and at least 6 weeks after maternal infection (earlier sampling yields false negatives because fetal renal excretion drives amniotic viral load); Toxoplasma B1-gene PCR after 18 weeks.
• Ultrasound/MRI findings that matter: periventricular calcifications and ventriculomegaly (CMV) versus diffuse scattered calcifications with hydrocephalus (toxoplasmosis); middle cerebral artery peak systolic velocity >1.5 multiples of the median is the validated noninvasive marker of fetal anemia in parvovirus B19.

Neonatal confirmation

• Congenital CMV requires urine or saliva PCR/culture obtained within the first 21 days of life; a positive saliva PCR is confirmed on urine. After 3 weeks, a positive test cannot distinguish congenital from perinatally acquired infection.
• Congenital syphilis: infant nontreponemal titer ≥4-fold (two dilutions) higher than the mother's, plus long-bone radiographs, CSF VDRL/cell count/protein, and CBC; CDC categorizes infants as confirmed/highly probable, possible, less likely, or unlikely, and this category dictates therapy.
• Neonatal HSV: surface swabs (conjunctiva, mouth, nasopharynx, rectum), vesicle, blood, and CSF HSV PCR.
• All infants need newborn hearing screening with serial audiology and ophthalmologic exam.

Organism-specific therapy

• Syphilis: parenteral penicillin G is the only acceptable regimen in pregnancy — benzathine penicillin G IM for early syphilis, stage-dependent dosing thereafter. A penicillin-allergic pregnant patient must undergo desensitization, not substitution; doxycycline and tetracyclines are contraindicated (fetal bone/tooth effects) and macrolides fail to cross the placenta reliably (CDC 2021 STI Treatment Guidelines). Proven or probable congenital syphilis: aqueous crystalline penicillin G IV or procaine penicillin G IM for 10 days.
• Toxoplasmosis: spiramycin (a macrolide that concentrates in placenta but crosses poorly) to reduce vertical transmission when fetal infection is not documented; once amniotic PCR confirms fetal infection or infection occurs after ~18 weeks, switch to pyrimethamine + sulfadiazine + leucovorin. Pyrimethamine is a folate antagonist and is avoided in the first trimester. Infected neonates receive pyrimethamine–sulfadiazine–leucovorin for about 12 months (AAP Red Book).
• CMV: no prenatal therapy is standard of care; CMV hyperimmune globulin is not recommended outside trials (SMFM), and high-dose valacyclovir remains investigational. Symptomatic congenital CMV, particularly with CNS disease, is treated with oral valganciclovir for 6 months (IV ganciclovir if enteral therapy is not tolerated), which improves hearing and neurodevelopmental outcomes; asymptomatic infants are not routinely treated (AAP Red Book).
• HSV: ACOG recommends suppressive acyclovir or valacyclovir from 36 weeks in women with recurrent genital herpes and cesarean delivery for active lesions or prodrome at labor. Neonatal disease: IV acyclovir 14 days (skin–eye–mouth) or 21 days (CNS/disseminated), then 6 months of oral acyclovir suppression.
• Varicella: VariZIG for susceptible exposed pregnant women and for neonates when maternal rash occurs 5 days before to 2 days after delivery; IV acyclovir for maternal varicella pneumonia.
• Parvovirus B19: no antiviral — intrauterine red cell transfusion for fetal anemia/hydrops.
• Rubella: supportive only. Prevention is MMR postpartum before discharge in nonimmune women; MMR and varicella vaccines are live and contraindicated during pregnancy (CDC/ACIP).

Disease complications

• Sensorineural hearing loss: cochlear and eighth-nerve injury from ongoing viral replication in CMV and from chronic rubella infection. It is frequently late-onset and progressive, so a passed newborn hearing screen does not exclude it — serial audiology through early childhood is mandatory.
• Obstructive hydrocephalus (toxoplasmosis): necrotizing periaqueductal inflammation obstructs the cerebral aqueduct. Bulging fontanelle, rapidly crossing head-circumference percentiles, sunsetting eyes, and apnea signal raised intracranial pressure — a neurosurgical emergency requiring shunting.
• Disseminated neonatal HSV: hepatic necrosis and DIC produce shock, transaminases in the thousands, and coagulopathy; this is the highest-mortality TORCH complication and is an emergency.
• Hydrops fetalis (parvovirus B19, syphilis): aplastic crisis or severe anemia causes high-output failure with ascites, effusions, and skin edema; untreated it progresses to intrauterine fetal demise.
• Chorioretinitis: toxoplasma cysts reactivate at the macula years later, causing vision loss into adolescence and adulthood — lifelong ophthalmologic follow-up.
• Late congenital rubella sequelae: insulin-dependent diabetes mellitus, thyroid disease, and rare progressive rubella panencephalitis.
• Late congenital syphilis stigmata: Hutchinson teeth, mulberry molars, saddle nose, saber shins, and interstitial keratitis.

Treatment complications

• Jarisch–Herxheimer reaction after penicillin for maternal syphilis: endotoxin-like cytokine surge from spirochete lysis causes fever, uterine contractions, and fetal heart-rate decelerations, and can precipitate preterm labor or fetal demise — treat in a setting with fetal monitoring; this is urgent but is never a reason to withhold penicillin.
• Valganciclovir: dose-limiting neutropenia (marrow suppression) — serial CBCs; also transaminitis and theoretical gonadal toxicity.
• Pyrimethamine: folate antagonism causing cytopenias — leucovorin rescue is given throughout therapy. Sulfadiazine: crystalluria, hypersensitivity/Stevens–Johnson syndrome, and displacement of bilirubin near term.
• Intrauterine transfusion: cord hematoma, fetal bradycardia, and procedure-related fetal loss.

• CMV is the most common congenital infection and the leading non-genetic cause of sensorineural hearing loss. Periventricular calcifications, microcephaly, and blueberry muffin rash (dermal extramedullary hematopoiesis) are the stem's tells.
• Best next step in a newborn with suspected congenital CMV: urine or saliva CMV PCR within the first 21 days of life. After 3 weeks you cannot separate congenital from perinatally acquired infection — this is the single most tested timing rule.
• Calcification pattern is the discriminator: periventricular = CMV; diffuse/scattered intracranial calcifications with hydrocephalus and chorioretinitis = toxoplasmosis (the classic triad).
• Rubella triad: patent ductus arteriosus (± peripheral pulmonic stenosis), cataracts, and deafness. A pregnant woman found non-immune is vaccinated postpartum, before discharge — MMR is live and contraindicated during pregnancy (CDC/ACIP).
• Penicillin-allergic pregnant patient with syphilis → desensitize and give penicillin G. Doxycycline is the distractor and is contraindicated (CDC 2021 STI Treatment Guidelines). Congenital syphilis is suspected when the infant's nontreponemal titer is ≥4-fold higher than the mother's; look for snuffles, hepatosplenomegaly, and the Wimberger sign of metaphyseal erosion.
• Parvovirus B19 → fetal anemia → hydrops. Follow MCA peak systolic velocity; >1.5 MoM triggers intrauterine transfusion. Parvovirus does not cause structural malformations.
• Neonatal vesicles, seizures, or sepsis-like illness → start IV acyclovir empirically, do not wait for PCR. Cesarean delivery is indicated for active genital lesions or prodrome at labor (ACOG).
• Common distractors: ordering a shotgun "TORCH titer panel" (low yield — order organism-specific tests); relying on a Tzanck smear for HSV; treating asymptomatic congenital CMV with valganciclovir (reserved for symptomatic/CNS disease per AAP); and assuming a normal newborn hearing screen excludes CMV-related hearing loss.